Worth reading
46Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Adipose-derived mesenchymal stromal cells (ASC) / ASC functional evaluation system using cytokine stimulation
Applicable field (uses covered by this announcement)
Regenerative medicine and treatment of immune-related diseases; quality evaluation of specified processed cell products
Launch date20 June 2026 (academic presentation; completed)
Relationship between the counterparty and the company
MEDINET Co.,Ltd.2370
Relationship with the Company
Relationship involving the presentation of research findings at the academic meeting
CounterpartyJapanese Society for Immunotherapy (23rd Annual Meeting of the Japanese Society for Immunotherapy)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
23rd Annual Meeting of the Japanese Society for Immunotherapy
| Item | Details |
|---|---|
| Names of Products / Services Covered | Adipose-derived mesenchymal stromal cells (ASC) / ASC functional evaluation system using cytokine stimulation |
| Counterparty | Japanese Society for Immunotherapy (23rd Annual Meeting of the Japanese Society for Immunotherapy) |
| Relationship with the Company | Relationship involving the presentation of research findings at the academic meeting |
| Launch date | 20 June 2026 (academic presentation; completed) |
| Applicable area | Regenerative medicine and treatment of immune-related diseases; quality evaluation of specified processed cell products |
| Source | 23rd Annual Meeting of the Japanese Society for Immunotherapy |
Items this document does not state (12)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The conventional T-cell proliferation inhibition assay requires the preparation of human-derived mononuclear cells and presents challenges in terms of the reproducibility of test results.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.